Home MarketDivi's Laboratories Ltd.

Divi's Laboratories Ltd. Stock Info: As on 2018-02-22 15:59:56

Nse

1019.25

12.50(1.24%)
Change%
52 Week Range
532.65
29.00
1,142.00
27.00
Open997.05
Day's Range906.08 - 1,107.43
Value Traded (in ₹ Cr.) 79.09

Bse

1015.10

6.60(0.65%)
Change %
52 Week Range
533.10
29.00
1,141.75
27.00
Open1,007.50
Day's Range907.65 - 1,109.35
Value Traded (in ₹ Cr.) 2.00

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 50,000.00 0.02%
IndianPromoters 138,181,232.00 52.05%
Mutual Funds/UTI 43,564,195.00 16.41%
FII 45,394,355.00 17.10%
Employee 0.00 0.00%
Public 22,194,372.00 8.36%
Government 0.00 0.00%
Others 15,227,532.00 5.74%
More

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 7.03
Basic EPS (Rs.) 41.73
Cash EPS 46.17
BVPerShare Excl 163.87
Operating Revenue 140.18
PBDITPerShare 56.21
Dividend 10.00
NPPerShare 41.73
Current Ratio 6.04
Quick Ratio 3.79
PriceToBV 6.01
Earnings 0.04
PBDIT Margin 40.10
PBT Margin 36.86
NP Margin 29.76
Return On Assets 22.03
Retention Ratios 76.03
Parameter Mar-16 (₹ Cr.) Yoy%change
Total Income 3,815.73
Total Expenses 2,443.89
EBITDA 1,492.26
PBT 1,371.84
PAT 1,107.69
Net Income 1,107.69
More
Parameter Mar-16 (₹ Cr.) 6M % change
Total Income 1,980.80
Total Expenses 1,287.13
EBITDA 634.56
PBT 691.91
PAT 568.78
Net Income 0.00
More
Total Assets
Total Assets
Parameter Mar-16 (₹ Cr.) Yoy%change
Total share capital 53.09
Net worth 4,350.14
Investments 805.35
Total Liability 5,027.50
Total debt 41.89
Net block 1,702.55
Total Assets 5,027.50
Parameter Sep-16 (₹ Cr.) 6M % change
Total share capital 53.09
Net worth 4,100.87
Investments 662.79
Total Liability 4,761.28
Total debt 36.68
Net block 1,590.62
Total Assets 4,761.28
Company Curr Price Prev. Close Change% W's Low/High

Aarti Drugs Ltd.

607 607.7 -0.12
603.6668.8

Abbott India Ltd.

5754.4 5640.3 2.02
5470.056125

Ajanta Pharma Ltd.

1350.3 1356.45 -0.45
1311.31420

Albert David Ltd.

365.2 368.6 -0.92
357.4395.35

Alembic Ltd.

60.8 60.8 0
60.363.45

Alembic Pharmaceuticals Ltd.

563.7 560.85 0.51
546.8585

Alkem Laboratories Ltd.

2174.8 2152.95 1.01
2115.12185
Company Curr Price Prev. Close Change% W's Low/High

Aarey Drugs & Pharmaceuticals Ltd.

48.75 49.5 -1.52
48.7554.15

Aarti Drugs Ltd.

604 607.05 -0.5
602.6680

Aayush Food & Herbs Ltd.

63.75 63.45 0.47
59.166.9

Abbott India Ltd.

5675 5637.6 0.66
5445.355950

ABL Bio-Technologies Ltd.

0.81 0.78 3.85
0.750.81

Addlife Pharma Ltd.

0.46 0 0
0.460.5

Adinath Bio-Labs Ltd.

0.3 0.31 -3.23
0.30.3
More
Parameter Mar-16(in ₹ Cr.)
Cash from operating activities 1,032.40
Cash from investing activities -413.43
Cash from financing activities -624.14
Net change in cash -5.17

Stock Held By Mutual Fund Schemes

Scheme Holding (%)
Reliance Equity Opportunities Fund 4.57%
SBI Magnum Balanced Fund 2.18%
SBI Blue Chip Fund 1.66%
Reliance Top 200 Fund 3.08%
HDFC Mid-Cap Opportunities Fund - Regular Plan 1.08%
Reliance Pharma Fund 10.35%

Enough assets to meet any liability, says scam-hit PNB

PNB said it has followed lawful avenues to recover its dues following Rs 11,400 crore swindling of funds allegedly by jewellery designer Nirav Modi and associates, reported PTI. The country's second largest public sector lender also reaffirmed that it has enough assets to meet any liability. We have followed lawful avenues available to us as per law of the land to recover our dues, the bank said in a regulatory filing. Stock exchanges had sought clarification on Modi's comment that PNB has closed all options to recover dues by going public. The bank had disclosed about the scam on February 14 through a regulatory filing. On why it did not inform stock exchanges about the filing of FIR with CBI at the occurrence of the event, PNB said: Since law enforcing agencies were assigned to investigate the matter, any news in public would have altered the fraudster, affecting recovery. The bank said on basis of preliminary investigation report, it had simultaneously informed its Board and BSE, NSE of initial fraud case of Rs 280.7 crore. Upon receiving further investigation report enhancing the fraud amount to Rs 11,394 crore, FMR (Fraud Monitoring Return) with RBI, FIR with CBI were filed in the evening of February 13, 2018, and BSE and NSE were informed on February 14 around 9 am, the bank said. About the impact of the scam on the financials and operations of the bank, it said: We have enough assets/ capital to meet any liability which is decided as per law.

22-02-2018 16:37

Merck board recommends dividend

Merck on Thursday said that its board has announced a dividend at the rate of Rs 15 per equity share. “The board of directors of the company at its meeting held on February 22, 2018, has recommended payment of dividend at the rate of Rs 15 per equity share of Rs 10 each for the year ended December 31, 2017,” Merck said in a filing to the Bombay Stock Exchange. Meanwhile, shares of company closed day’s trade at Rs 1443.90 apiece, down 0.92 per cent, on the Bombay Stock Exchange.

22-02-2018 16:35

Sanofi board recommends final dividend

Sanofi India on Thursday said that its board has recommended a final dividend of Rs 53 per equity share of Rs 10 for the year ended December 31, 2017. “An interim dividend of Rs 18 per equity share of Rs 10 was paid in August 2017. The interim dividend and the proposed final dividend totalling to Rs 71 per equity share of Rs 10, will together amount to a distribution of Rs 1,633 million (excluding dividend distribution tax),” Sanofi India said in a filing to the Bombay Stock Exchange. Meanwhile, shares of company closed day’s trade at Rs 4833.20 apiece, down 0.10 per cent, on the Bombay Stock Exchange.

22-02-2018 16:34

BSE signs pact with Soybean Processors Association of India

BSE signed a pact with Soybean Processors Association of India (SOPA) for the growth and development of commodity market and its value-chain participants, enabling them to manage price risk in a better manner in the soyabean oil complex, reported PTI. The agreement will be beneficial for launching products like soybean, soyoil and soymeal futures trading on BSE, the exchange said in a statement issued here. BSE and SOPA have made significant progress in their respective areas for the growth and development of the commodity market and will share knowledge and expertise in this regard, the it added. BSE MD and CEO Ashishkumar Chauhan said, BSE and SOPA fully acknowledge each other's respective strengths, resources, experience and expertise and therefore feel it expedient to join hands for mutual benefits in pursuit of common goals with the underlying objective of developing commodity derivatives market. BSE (formerly Bombay Stock Exchange), established in 1875, is Asia's oldest stock exchange, while SOPA is the only national-level body representing the soybean processors, farmers, exporters and brokers in India working towards strengthening soybean as a viable crop. Last month, BSE conducted mock-trading for commodity derivatives segment as it prepares itself for the launch of trade in such products. The platform currently offers trading in equities, equity derivatives as well as currency derivatives.

22-02-2018 16:25

Sundaram Equity Plus: change in investment factsheets for January

Sundaram Equity Plus has announced change in investment factsheets and fund flash for the month ended January 31, 2018. As on Jan 31, 2018, the total size of the Fund was Rs 42.22 crores, compared with Rs 41.16 crores in the last month. The Fund's NAV per unit was Rs 15.65 for Growth, while 52-Week High and Low ranges were Rs 16.37 and Rs 13.92 respectively. The Equity - Diversified fund with Growth plan was launched on May 04, 2011 and managed by Fund Manager Rahul Baijal. The top five companies based on a percentage of total holdings were HDFC Bank Ltd (2.41 Cr.), Housing Development Finance Corporation Ltd (2.15 Cr.), Reliance Industries Ltd (2.11 Cr.), ICICI Bank Ltd (2.10 Cr.) and Infosys Ltd (1.98 Cr.). Sundaram Equity Plus is promoted by Sundaram Mutual Fund and managed by Sundaram Asset Management Company Ltd..

22-02-2018 15:30

Divi's Lab Q3 net profit down 16.27% at Rs 224.66 cr

The company reported standalone net profit of Rs 224.66 crore for the quarter ended December 31, 2017 as compared to Rs 268.32 crore in the same period last year, registering a year-on-year decline of 16.27 per cent. Net revenue of the company rose moderately by 6.62 per cent at Rs 1,037.88 crore in October-December quarter of this fiscal as against Rs 973.44 crore in the corresponding period last year. During October-December quarter, operating expenses increased by 19.48 per cent to Rs 711.74 crore from Rs 595.68 crore in year ago period. Other Income dipped by 7.90 per cent at Rs 17.01 crore versus (Dec'16 Rs 18.47 crore). Operating Profit slipped by 14.35 per cent to Rs 326.14 crore as against Rs 380.80 crore in the year ago period, while Operating Profit Margin (OPM) contracted year-on-year to 19.68 per cent in December quarter. Interest declined by 40.91 per cent y-o-y to Rs 0.26 crore, while Taxation decreased by 18.80 per cent at Rs 80.84 crore (Dec'16 Rs 99.56 crore).

01-Feb-2018 11:28 AM

Divi's Lab - Financial Results For December 31, 2017

Further to our letter dated 18th January, 2018, we would like to inform that the Board of Directors of the Company at its meeting held on Saturday, 27th January 2018 has approved Un-audited Financial Results for the quarter and nine months ended 31st December, 2017.

In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we are enclosing herewith the following:

1. Un-audited Standalone Financial Results for the quarter and nine months ended 31st December, 2017.
2. Limited Review Report on the Standalone Financial Results
3. Press Release on the Financial Results of the Company

The Board meeting commenced at 15:30 Hrs and concluded at 17:30 Hrs

27-Jan-2018 05:41 PM

Divi's Lab - Financial Result Updates

Divi''s Laboratories Limited has submitted to the Exchange, the financial results for the period ended December 31, 2017.

27-Jan-2018 05:39 PM

Divi's Lab - Board Meeting On January 27, 2018

Notice is hereby given that a meeting of Board of Directors of the Company is scheduled to be held on Saturday, the 27th day of January 2018 to consider and approve, inter-alia, the un-audited financial results for the quarter and nine months ended 31st December 2017.

We further inform you that the Trading Window for dealing in securities of the Company shall remain closed for insiders of the company from January 20, 2018 to January 29, 2018 (both days inclusive) as per the Code of Conduct of the Company under the SEBI (Prohibition of Insider Trading) Regulations, 2015.

18-Jan-2018 04:01 PM

Divi's Lab - Statement Of Investor Complaints For The Quarter Ended 31St December 2017.

In compliance with Regulation 13 (3) of SEBI (LODR) Regulations, 2015, please find below the statement of investors complaints for the quarter ended 31st December, 2017:

S.No. Particulars Number
1 Number of complaints pending at the beginning of the quarter Nil
2 Number of complaints received during the quarter 14
3 Number of complaints disposed of during the quarter 14
4 Number of complaints remaining unresolved at the end
of the quarter Nil


10-Jan-2018 12:44 PM

Divi's Lab - Financial Results For December 31, 2017

Further to our letter dated 18th January, 2018, we would like to inform that the Board of Directors of the Company at its meeting held on Saturday, 27th January 2018 has approved Un-audited Financial Results for the quarter and nine months ended 31st December, 2017.

In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we are enclosing herewith the following:

1. Un-audited Standalone Financial Results for the quarter and nine months ended 31st December, 2017.
2. Limited Review Report on the Standalone Financial Results
3. Press Release on the Financial Results of the Company

The Board meeting commenced at 15:30 Hrs and concluded at 17:30 Hrs

27-Jan-2018 05:41 PM

Divi's Lab - Board Meeting On January 27, 2018

Notice is hereby given that a meeting of Board of Directors of the Company is scheduled to be held on Saturday, the 27th day of January 2018 to consider and approve, inter-alia, the un-audited financial results for the quarter and nine months ended 31st December 2017.

We further inform you that the Trading Window for dealing in securities of the Company shall remain closed for insiders of the company from January 20, 2018 to January 29, 2018 (both days inclusive) as per the Code of Conduct of the Company under the SEBI (Prohibition of Insider Trading) Regulations, 2015.

18-Jan-2018 04:01 PM

Divi's Lab - Statement Of Investor Complaints For The Quarter Ended 31St December 2017.

In compliance with Regulation 13 (3) of SEBI (LODR) Regulations, 2015, please find below the statement of investors complaints for the quarter ended 31st December, 2017:

S.No. Particulars Number
1 Number of complaints pending at the beginning of the quarter Nil
2 Number of complaints received during the quarter 14
3 Number of complaints disposed of during the quarter 14
4 Number of complaints remaining unresolved at the end
of the quarter Nil


10-Jan-2018 12:44 PM

Corporate Details

About Management

Milestones: 1990 -Divis Research Center (DRC) established. 1991-1993 -DRC successfully develops several commercial processes for intermediates and bulk actives and supplies to manufacturing majors. 1994 -Divis Research Center changes its name to Divis Laboratories Limited to reflect its growing area of operations and its plans to enter the manufacturing sector in the following year. 1995 -Manufacturing Facility (Unit-1) at Choutuppal near Hyderabad starts operations. 1997 -SGS-Yarsley of U.K certifies Divis Laboratories as ISO-9002 compliant. 1999 -European Directorate gives a "Certificate of Suitability" (CoS) for Naproxen produced at Divis Laboratories. 2000 -US-FDA inspects Divis Laboratories successfully SGS-Yarsley of U.K awards Divis the ISO 9001 Certification SGS International AG of Switzerland awards Divis the ISO-14001 Certification (for its efficient Environment Management Systems). 2001 -BVQI of London awards Divis the OHSAS-18001 Certification (for its Occupational Health and Safety Management Systems). 2002 -Divis commences the setting up of its 2nd Manufacturing Facility (Unit-2) at Chippada near Visakhapatnam. 2003 -Divis opens a new research center christened `DRC-Vizag' for fundamental research in selected niche business core segments. -Went for IPO and listed on stock exchanges BSE, NSE and HSE. -Divi's Laboratorie receives Certificate of Substantiability from the council of Europe -Appointed Mr A Narendra as Company Secretary & Compliance Officer of the company (in place of outgoing Company Secretary Mr P Sudarshan) who has joined the organization. 2004 - Divi'S Laboratories Limited has informed that the manufacturing facility of Divi's Labs at Choutuppal near Hyderabad was successfully inspected by US-FDA in May 2004. -US-FDA inspects the Choutuppal (Unit-1) for a second time. No 483. 2006 -Delists equity shares form The Hyderabad Stock Exchange Ltd (HSE), Hyderabad with effect from March 29, 2006. -US-FDA inspects the Visakhapatnam(Unit-2) for the first time. 2007 - The Company has splits its face value from Rs10/- to Rs2/-. 2008 -Third US-FDA inspection for Choutuppal(Unit-1). 2009 - Certified and Awarded for "Best Green Belt Development" - SURAKSHA PURASKAR for the year 2008 - ISO 14001: 2004 (Re-Certification) "Environment Management System" -Divi's Laboratories has given the Bonus in the Ratio of 1:1 2010 - Divis Lab - Setting up of a new Unit in SEZ at Visakhapatnam. - The Company has recommended a dividend of 300% i.e. Rs. 6/- per equity share of Rs. 2/- face value for the year ended March 31, 2010. 2011 - Divi’s Laboratories surged 3.5 per cent in early morning trade on Bombay Stock Exchange on November 2, 2011, after the announcement of healthy growth in Q2 numbers on November 1, 2011, after trading hours. - Shares of the company after opening higher at Rs 765 from previous close of Rs 759.20, rose to hit a high of Rs 785.40 on BSE, reflecting the gain of 3.5 per cent. At 11:05 AM, the stock was trading at Rs 772.85 on Bombay Stock Exchange. 2012 - Divis Laboratories Ltd has informed BSE that the Board of Directors through Circular resolution dated March 07, 2012 has decided to seek shareholders approval by postal ballot for Re-appointment and revision in remuneration of Mr. Madhusudana Rao Divi as Director-Projects of the Company. - The Company Re-appointment and revision in remuneration of Mr. Kiran S. Divi Director & President- Operations of the Company. - Enhancement of remuneration of Dr. Murali K. Divi, Chairman & Managing Director of the Company. - Enhancement of remuneration of Mr. N. V. Ramana, Executive Director of the Company. 2013 -Divis Laboratories Ltd. has recommended a dividend of 750% i.e. Rs. 15/- per equity share of Rs. 2/- face value for the year ended March 31, 2013. 2014 -Divis Laboratories Ltd. has recommended a dividend of 1000% i.e. Rs. 20/- per equity shares of Rs. 2/- face value for the year ended March 31, 2014. 2015 -Divis Laboratories Ltd has approved to give bonus shares on the eve of 25th year of formation of the Company, in the ratio of 1:1. 2016 -Divis Labs unit-2 at Chippada successfully inspected by USFDA

Registered Office

DSN SEZ Unit : Chippada Village, Bheemunipatnam Mandal,

,,,      ,

Registrar Details

Karvy Computershare Private Ltd.